PDCD1 and non-small cell lung carcinoma: STK11m have been associated with inferior clinical outcomes with PD-1 blockade in multiple independent cohorts of KRASm NSCLC, including patients with KRASm non-squamous NSCLC treated with nivolumab in the CheckMate 057 study [19].